Successful desensitization and kidney transplantation in the presence of donor-specific anti-human leukocyte antigen antibodies in kidney transplant recipients
المؤلفون المشاركون
Ahmad, Jalil
Khan, Muhammad Tasadduq
Lal, Naranjan
Bin Hamid, Rashid
Sarfaraz, Sabahat
Luxmi, Shobha
المصدر
Saudi Journal of Kidney Diseases and Transplantation
العدد
المجلد 31، العدد 6 (31 ديسمبر/كانون الأول 2020)، ص ص. 1432-1438، 7ص.
الناشر
تاريخ النشر
2020-12-31
دولة النشر
السعودية
عدد الصفحات
7
التخصصات الرئيسية
الملخص EN
Kidney transplantation has indisputably revamped renal medicine and restored hope among patients coming across fatal end-stage renal disease.
However, sensitization of human leukocyte antigen (HLA) triggers extensive immunological fences to successful kidney transplantation and henceforth, transplant candidates are frequently demoted to the ever-growing waiting list owing to preformed donor specific antibodies (DSAs).
Over the past few years, the advent of desensitization protocols has significantly overpowered the immunological barriers and enhanced the outcomes of kidney transplant recipients with DSAs against HLA.
Those desensi- tization protocols include combination of plasmapheresis, high-dose intravenous immunoglobulin (IVIG), low-dose IVIG, rituximab, and/or bortezomib.
These immunomodulatory treatments either eliminate DSAs or prevent their production.
Lately, our transplant center developed and used a desensitization protocol (Two sessions of plasmapheresis on day 1 and 2 → injection rituximab on day 2 after plasmapheresis →no plasmapheresis on day 3 → eight sessions of plasmapheresis after day 3 and IVIG 100 mg/Kg/dose after each session of plasmapheresis → repeat HLA antibody detection test to confirm if DSAs are present against HLA with median fluorescence intensity (MFI)values <1000 and complement dependent cytotoxicity (CDC) crossmatch is negative for both T and B lymphocytes; if NO then continue plasmapheresis sessions with IVIG 100 mg/kg/dose till MFI values are <1000 and CDC crossmatch is negative for both T and B lymphocytes or if YES then proceed for transplantation → repeat dose of rituximab post-transplantation) to evaluate its effectiveness in improving kidney function in patients post-desensitization and kidney transplantation.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Khan, Muhammad Tasadduq& Bin Hamid, Rashid& Sarfaraz, Sabahat& Lal, Naranjan& Ahmad, Jalil& Luxmi, Shobha. 2020. Successful desensitization and kidney transplantation in the presence of donor-specific anti-human leukocyte antigen antibodies in kidney transplant recipients. Saudi Journal of Kidney Diseases and Transplantation،Vol. 31, no. 6, pp.1432-1438.
https://search.emarefa.net/detail/BIM-1247368
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Khan, Muhammad Tasadduq…[et al.]. Successful desensitization and kidney transplantation in the presence of donor-specific anti-human leukocyte antigen antibodies in kidney transplant recipients. Saudi Journal of Kidney Diseases and Transplantation Vol. 31, no. 6 (Nov. / Dec. 2020), pp.1432-1438.
https://search.emarefa.net/detail/BIM-1247368
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Khan, Muhammad Tasadduq& Bin Hamid, Rashid& Sarfaraz, Sabahat& Lal, Naranjan& Ahmad, Jalil& Luxmi, Shobha. Successful desensitization and kidney transplantation in the presence of donor-specific anti-human leukocyte antigen antibodies in kidney transplant recipients. Saudi Journal of Kidney Diseases and Transplantation. 2020. Vol. 31, no. 6, pp.1432-1438.
https://search.emarefa.net/detail/BIM-1247368
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references : p. 1438
رقم السجل
BIM-1247368
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر